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The hect domain protein family was originally identi-
fied by sequence similarity of its members to the C-
terminal region of E6-AP, an E3 ubiquitin-protein ligase.
Since the C terminus of E6-AP mediates thioester com-
plex formation with ubiquitin, a necessary intermediate
step in E6-AP-dependent ubiquitination, it was pro-
posed that members of the hect domain family in gen-
eral have E3 activity. The hect domain is approximately
350 amino acids in length, and we show here that the
hect domain of E6-AP is necessary and sufficient for
ubiquitin thioester adduct formation. Furthermore, the
human genome encodes at least 20 different hect do-
main proteins, and in further support of the hypothesis
that hect domain proteins represent a family of E3s,
several of these are shown to form thioester complexes
with ubiquitin. In addition, some hect domain proteins
interact preferentially with UbcH5, whereas others in-
teract with UbcH7, indicating that human hect domain
proteins can be grouped into at least two classes based
on their E2 specificity. Since E3s are thought to play a
major role in substrate recognition, the presence of a
large family of E3s should contribute to ensure the spec-
ificity and selectivity of ubiquitin-dependent proteo-
lytic pathways.
Ubiquitin-dependent degradation operates through a two
step mechanism (for recent reviews, see Refs. 1–5). Firstly,
ubiquitin is covalently attached to a substrate protein. Ubiq-
uitin itself can then serve as a substrate for ubiquitin conjuga-
tion (ubiquitination) which results in the formation of polyu-
biquitin chains. Finally, ubiquitinated proteins are recognized
and degraded by the 26 S proteasome or, as shown for some
membrane proteins, internalized and degraded via the lysoso-
mal pathway (6–8).
Ubiquitination of proteolytic substrates requires the con-
certed action of ubiquitin-activating enzymes E1,1 ubiquitin-
conjugating enzymes E2, and probably in most cases, ubiq-
uitin-protein ligases E3 (1–5). First, ubiquitin is activated at
the expense of ATP and is covalently linked to E1 via a thio-
ester bond. Ubiquitin is then transferred from the E1 to an E2,
preserving the high energy thioester bond. Finally, the cova-
lent attachment of ubiquitin to a substrate protein is catalyzed
by the E2s, often in conjunction with an E3. Although the
mechanisms of substrate recognition are still poorly under-
stood, this sequential mode of ubiquitin transfer indicates that
E2s and, in particular, E3s play a major role in mediating
substrate recognition.
Based on their mode of action, E3s can be classified into two
categories. Some E3s may function as docking proteins by
binding specifically to substrate proteins and E2s, thereby al-
lowing E2s to ubiquitinate substrate proteins. Such E3s may be
represented by the recently identified SCF complexes (9, 10).
SCF complexes consist of CDC53, SKP1, and one of a number
of F-box proteins (e.g. Cdc4, Grr1) (11), which appear to deter-
mine the substrate specificity of the respective SCF complex (9,
10). Furthermore, SCF complexes have been shown to cooper-
ate with the E2 UBC3/Cdc34 in the ubiquitination of substrate
proteins. Other E3s appear to directly catalyze the attachment
of ubiquitin to a substrate protein, since some E3s are loaded
with ubiquitin by E2s via thioester formation. E3s with thio-
ester-forming capacity include yeast UBR1 (5), mammalian
E6-AP (12), and presumably the members of an E6-AP-related
family of putative E3s termed hect domain proteins (12, 13).
Members of this family have been described in all eukaryotes
examined and are characterized by a C-terminal region of
approximately 350 amino acids in length, the hect domain
(homologous to E6-AP C terminus).
E6-AP was originally identified as a protein that is required
for ubiquitination of the tumor suppressor protein p53 induced
by the E6 oncoprotein of HPVs associated with cervical cancer
(14, 15). Subsequent studies revealed that E6-AP has the func-
tion of an E3 (16). Furthermore, it was shown that E6-AP forms
thioester complexes with ubiquitin in the presence of E1 and
distinct E2s, and the position of the putative catalytic site
cysteine residue was mapped to the C terminus (12). The posi-
tion of this cysteine residue as well as of several surrounding
residues is highly conserved among hect domain proteins, sug-
gesting that these proteins in general share the ability to form
ubiquitin thioester adducts. In support of this hypothesis, three
hect domain proteins from three different organisms, Saccha-
romyces cerevisiae RSP5, Schizosaccharomyces pombe Pub1,
and a rat 100-kDa protein have been shown to form thioester
complexes with ubiquitin (13, 17).
The turnover of many cellular proteins appears to involve
ubiquitin-dependent pathways, indicating that a cell contains a
number of different E3s with different substrate specificities.
Indeed, the genome of S. cerevisiae encodes for five hect domain
proteins (4), of which two (RSP5, UFD4) have been shown to be
involved in the degradation of natural as well as of artificial
substrate proteins (18–20). Here we report that the minimal
domain of E6-AP and RSP5 required for ubiquitin thioester
formation coincides with the size of the hect domain. Based on
this information, data base searches revealed that the human
genome encodes at least 20 different hect domain proteins.
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Ubiquitin thioester complex formation assays show that hu-
man hect domain proteins can be classified into two groups
based on their preference for distinct E2s. Finally, generation
of chimeric proteins between E6-AP and other hect domain
proteins indicates that hect domains are not freely inter-
changeable but rather that a given hect domain has to be in a
proper structural context to induce ubiquitination of associated
proteins.
EXPERIMENTAL PROCEDURES
Plasmids—The p53 plasmid for in vitro transcription and translation
has been described previously (21). Expression plasmids encoding the
various N-terminal-truncated E6-AP forms, the N-terminal-truncated
forms of RSP5, and the hect domains of seven different human hect
domain proteins were constructed by ligating PCR products into
pGEM-1 for in vitro transcription and translation. Expression plasmids
encoding the hect domain of E6-AP and the E6-AP/p532 chimeric pro-
tein consisting of amino acids 200–491 of human E6-AP isoform 1 (22)
fused to amino acids 4495–4861 of p532 (23, 24) were constructed by
ligating PCR products into pGEX-2TK for bacterial expression. The
cDNAs used as templates in PCR for E6-AP, RSP5, and p532 (hectH6)
have been described (13, 15, 23). cDNAs encoding the hect domain of
human hect domain proteins other than E6-AP and p532 were obtained
from the following sources: hectH2 (GenBank accession number
D13635) and hectH3 (D25215) were kindly provided by N. Nomura;
hectH4 (D28476) and hectH5 (D42055) were obtained by RNA PCR
using cytoplasmic RNA prepared from HeLa cells; hectH9 (human
homolog to a rat protein termed UREB1, accession number U08214)
was obtained by RNA PCR followed by screening of a HeLa cDNA
library (CLONTECH); hectH7 was obtained from two EST clones (ac-
cession numbers T93069 and H19362; I.M.A.G.E. consortium). Plas-
FIG. 1. The hect domain of E6-AP is
necessary and sufficient for ubiq-
uitin thioester formation. A, schematic
representation of N-terminal-truncated
forms of E6-AP. The various forms of
E6-AP were generated in rabbit reticulo-
cyte lysate and tested for ubiquitin thio-
ester complex formation (see below). The
ability of the different E6-AP truncation
mutants to form ubiquitin thioester ad-
ducts is indicated. 1, forms ubiquitin
thioesters with a similar efficiency as the
95-kDa form of E6-AP; 1/2, significantly
less efficient in ubiquitin thioester forma-
tion than the 95-kDa E6-AP; 2, thioester
complex formation was not observed. The
95-kDa E6-AP represents the form com-
monly used in studies concerning E6-AP
function. The putative catalytic site cys-
teine residue (C) at amino acid position
820 (12) is marked as a white bar. Num-
bering of the amino acid residues is ac-
cording to E6-AP isoform 1 (22). B, the
indicated E6-AP forms were generated in
rabbit reticulocyte lysate in the presence
of L-[35S]methionine and partially puri-
fied by anion exchange chromatography
(see “Experimental Procedures”) to re-
move endogenous ubiquitin (Ub) and
those E2s present in reticulocyte lysate
that are known to interact with E6-AP
(26, 27, 29, 30). The partially purified ra-
diolabeled E6-AP forms were then incu-
bated in the absence (input) or in the
presence of ubiquitin or GST-ubiquitin,
E1, and the respective recombinant E2s
as indicated. After 5 min at 25 °C, the
reactions were stopped in the absence or
presence of a reducing agent and sub-
jected to SDS-polyacrylamide gel electro-
phoresis as described previously (12). The
reactions stopped in the presence of a re-
ducing agent are not shown, but it should
be noted that, under these conditions, the
ubiquitin adducts of E6-AP observed in
the absence of a reducing agent could not
be detected. This indicates that the ob-
served ubiquitin adducts indeed repre-
sent thioester complexes of ubiquitin with
the respective E6-AP form. Furthermore,
the band observed just below the DN491
form of E6-AP could not be detected in the
presence of a reducing agent, indicating
that it is a modified form of DN491 that is
susceptible to reducing conditions. This
suggests that DN491 may contain an in-
tramolecular disulfide bond(s) under non-
reducing conditions.
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mids encoding the GST-ubiquitin fusion protein and the 75-kDa form of
E6-AP as a GST fusion protein have been described (16).
Protein Expression—E1, UbcH1, UbcH5, UbcH6, and UbcH7 were
expressed in Escherichia coli BL21(DE3) using the pET expression
system as described previously (25–27). For ubiquitination and ubiq-
uitin thioester formation assays, E1 was partially purified by anion
exchange chromatography as described (16). As a source of UbcH1,
UbcH5, UbcH6, or UbcH7, crude bacterial extracts containing the re-
spective E2s were used.
The GST fusion proteins (ubiquitin, 75-kDa form of E6-AP, hect
domain of E6-AP, E6-AP/p532 chimeric protein, and E6-E7) were ex-
pressed in E. coli DH5a, affinity-purified on glutathione-Sepharose
(Amersham Pharmacia Biotech) and eluted with 10 mM glutathione. In
experiments using radiolabeled ubiquitin, the GST-ubiquitin fusion
protein was radioactively labeled while bound to glutathione-Sepharose
using protein kinase A (Sigma) in the presence of [g-32P]ATP (16). The
radiolabeled fusion protein was eluted with 10 mM glutathione and
cleaved with thrombin (Novagen) to yield free ubiquitin. Upon cleavage,
thrombin was inactivated by incubation at 75 °C for 15 min.
For in vitro expression, the various proteins (p53, hect domains, and
N-terminal truncation mutants of E6-AP and RSP5) were generated by
in vitro transcription-translation. Transcription and translation was
performed according to the manufacturer’s instructions (Promega).
Translation was performed in rabbit reticulocyte lysate or in wheat
germ extract in the presence of L-[35S]methionine as indicated in the
text.
As a source of the HPV-16 E6 oncoprotein, E6 was prepared from
insect cells (High Five cells; Invitrogen) infected with a recombinant
baculovirus expressing E6 (kindly provided by J. M. Huibregtse). For
partial purification of E6, crude extracts from infected insect cells were
loaded onto a Mono S column (Amersham), the column was washed with
25 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM DTT, and bound proteins
were eluted with 400 mM NaCl.
Thioester, Ubiquitination, and p53 Binding Assays—L-[35S]Methi-
onine-labeled forms of E6-AP and RSP5 synthesized in vitro in rabbit
reticulocyte lysate were partially purified by anion exchange chroma-
tography as follows. 100 ml of rabbit reticulocyte lysate programmed
with mRNA encoding for the respective proteins were loaded onto a
Mono Q column (Amersham), the column was washed with 25 mM
Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM DTT, and bound proteins were
eluted with 500 ml of the same buffer but containing 400 mM NaCl
instead of 50 mM NaCl. 10 ml of the partially purified proteins were
tested in ubiquitin thioester formation assays in the presence of E1, E2s
as indicated (UbcH1, UbcH5, UbcH6, UbcH7), and native ubiquitin or
GST-ubiquitin as described previously (12, 27). Similar amounts of the
different E2s were used as assessed by their ability to form thioester
complexes with 32P-labeled ubiquitin in the presence of E1. To test the
capacity of the hect domain of human hect domain proteins to form
ubiquitin thioester complexes, the respective hect domains were trans-
lated in rabbit reticulocyte lysate, and 5 ml of the respective translate
were used in standard ubiquitin thioester formation assays as described
above. Thioester formation assays using GST fusion proteins (GST-hect
E6-AP, GST-75 kDa E6-AP, GST-E6-AP/p532) were performed using
32P-labeled ubiquitin as described for baculovirus-expressed E6-AP
(12).
p53 ubiquitination assays were performed as described (16) using
wheat germ extract-translated p53, partially purified HPV-16 E6 ex-
pressed in insect cells, and 1 mg of GST-75 kDa E6-AP, GST-E6-AP/
p532, or GST-hect E6-AP. Ubiquitination assays using bacterially ex-
pressed GST-E6-E7 as a substrate were performed as described (16).
p53 binding assays using GST fusion proteins (GST-hect E6-AP,
GST-75 kDa E6-AP, and GST-E6-AP/p532) in the presence of the
HPV-16 E6 oncoprotein were performed as described (28). As a source of
radiolabeled p53, p53 expressed in wheat germ extract was used.
RESULTS
The hect Domain of E6-AP or RSP5 Is Necessary and Suffi-
cient for Ubiquitin Thioester Formation—The hect domain pro-
teins are characterized by a conserved C-terminal region of
approximately 350 amino acids (13), suggesting that this re-
gion may be necessary and sufficient to form thioester com-
plexes with ubiquitin in the presence of distinct E2s. To test
this hypothesis, a series of N-terminal-truncated forms of
E6-AP (Fig. 1A) were generated in vitro using the rabbit re-
ticulocyte lysate system. The resulting E6-AP forms were then
partially purified by anion exchange chromatography to re-
move endogenous ubiquitin as well as E2 activities present in
rabbit reticulocyte lysate that are known to interact with
E6-AP (26, 27, 29, 30). Finally, the partially purified forms of
E6-AP were tested for ubiquitin thioester formation in the
absence or presence of distinct E2s, i.e. UbcH1 (the human
homolog of S. cerevisiae UBC2/RAD6), UbcH5 (the human hom-
olog of S. cerevisiae UBC4/UBC5), UbcH6, and UbcH7 (Fig. 1)
(26, 27, 31). This revealed that the minimal domain of E6-AP,
which is necessary and sufficient for ubiquitin thioester forma-
tion, comprises amino acid residues 492–852 (numbering is
according to the sequence of E6-AP isoform 1 (22)). It should be
noted that C-terminal-truncated forms were not generated,
since the putative catalytic site cysteine residue of E6-AP is
located at amino acid residue 820 (12), and thus, the informa-
tion obtained in a deletion analysis of the C terminus would be
rather limited.
As expected from previous studies (26, 27), thioester forma-
tion of all the E6-AP forms tested was observed in the presence
of UbcH5 and UbcH7 but not UbcH1. Additionally, thioester
formation was not observed in the presence of UbcH6. This is in
contrast to the results obtained previously with the 95-kDa
form of E6-AP expressed in the baculovirus system that was
reported to form thioester complexes in the presence of UbcH6
although significantly less efficiently than in the presence of
UbcH5 or UbcH7 (27). The reason for this apparent difference
is presently unknown, but it may simply reflect different sen-
sitivities of the respective thioester assays.
FIG. 2. The hect domain of RSP5 is necessary and sufficient for
ubiquitin thioester formation. Two N-terminal truncation mutants
of S. cerevisiae RSP5 comprising amino acids 447–809 (DN446) and
473–809 (DN472), respectively, were generated in rabbit reticulocyte
lysate in the presence of L-[35S]methionine and partially purified by
anion exchange chromatography (see “Experimental Procedures”). The
radiolabeled RSP5 forms were then incubated in the absence (input) or
presence of ubiquitin (Ub) or GST-ubiquitin, E1, and the respective
recombinant E2s as indicated. After 5 min at 25 °C, reaction mixtures
were stopped in the absence or presence of a reducing agent and sub-
jected to SDS-polyacrylamide gel electrophoresis as described previ-
ously (12). The reactions stopped in the presence of a reducing agent are
not shown but it should be noted that, under these conditions, the
ubiquitin adducts of RSP5 observed in the absence of a reducing agent
could not be detected. This indicates that the observed ubiquitin ad-
ducts represent thioester complexes of ubiquitin with the respective
RSP5 form.
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Based on the results obtained for E6-AP, two N-terminal
truncation mutants of S. cerevisiae RSP5 were generated (for
sequence comparison, see Fig. 3A) and tested for ubiquitin
thioester formation. Similar to E6-AP, a deletion mutant of
RSP5 comprising amino acid residues 447–809 was active in
ubiquitin thioester formation, whereas deletion of the N-termi-
nal 472 amino acids resulted in an inactive form of RSP5 (Fig.
2). Thioester formation of the truncated form of RSP5 was
observed in the presence of UbcH5, UbcH7, and, to a lesser
extent, UbcH6. In this context it should be noted that in this
experiment, as well as in all the other ubiquitin thioester
experiments presented, similar amounts of UbcH1, UbcH5,
UbcH6, and UbcH7 were used as determined by their ability to
form thioester complexes with radioactively labeled ubiquitin
in the presence of E1. Furthermore, titration experiments us-
ing decreasing amounts of the respective E2s were performed.
This showed that UbcH5 and UbcH7 were similarly active in
transferring ubiquitin to the truncated form of RSP5, even
under conditions where the amounts of UbcH5 and UbcH7 used
were rate-limiting.2 Again, this is in contrast to results previ-
ously obtained with baculovirus expressed RSP5 (27). In this
case, UbcH7 was significantly less efficient in loading RSP5
with ubiquitin than UbcH5. The reason for this discrepancy is
presently unclear.
Human hect Domain Family Members Interact Preferentially
with UbcH5 or UbcH7—Sequence alignment of the minimal
region of E6-AP and RSP5 necessary for ubiquitin thioester
formation with the amino acid sequences of other hect domain
proteins present in available data bases revealed that this
region coincides with the size of the region that appears to be
conserved among all known members of the hect domain family
(Fig. 3A). To obtain further evidence that a general feature of
hect domain family members is the capacity to form thioester
complexes with ubiquitin, the cDNAs encoding the hect domain
of seven different human hect domain proteins were obtained
(for further details, see “Experimental Procedures”). The re-
spective proteins were expressed in the reticulocyte lysate sys-
tem and tested for ubiquitin thioester formation without fur-
ther purification. As summarized in Fig. 4, six of these proteins
formed thioester complexes with ubiquitin, whereas one desig-
nated as hectH5 was inactive in the presence of the E2s used in
this study (see “Discussion”). Furthermore, it appears that
human hect domain proteins can be grouped into two classes
based on their interaction with distinct E2s. Some hect domain
proteins (e.g. hectH6 that represents the recently identified
protein p532 (23, 24); Fig. 4A) form ubiquitin thioester com-
plexes preferentially in the presence of UbcH5, whereas others
(e.g. hectH7; Fig. 4B) form thioester complexes preferentially in
the presence of UbcH7.
It is widely assumed that E3s play a major role in the
recognition of substrates of the ubiquitin-conjugating system.
Therefore, to ensure the specificity and selectivity of ubiquitin-
dependent degradation, it seems likely that a cell contains a
number of different hect domain proteins involved in the deg-
radation of different proteins. This notion is supported by
Northern blot analyses showing that the genes encoding the
hect domain proteins tested in this study are coexpressed in
several tissues, most prominently in skeletal muscle (Fig. 5),
and by RNA PCR analyses demonstrating that at least six of
the eight human hect domain genes tested are expressed in the
cell lines HeLa (cervical carcinoma) and H1299 (non-small cell
lung cancer).22 S. E. Schwarz and M. Scheffner, unpublished data.
FIG. 3. The human hect domain family. Using amino acid residues 814–852 of E6-AP isoform 1 (22) as a query sequence, data base searches
indicate that the human genome encodes at least 20 different hect domain proteins. In A, the amino acid sequence of the N-terminal and C-terminal
ends of the hect domains is shown, for which cDNA sequences are available encoding the respective full-length hect domain protein. The putative
catalytic site cysteine residue is marked with an asterisk. The amino acid numbers comprising the minimal hect domain of E6-AP and RSP5 as
determined in the experiments shown in Fig. 1 and Fig. 2 are indicated. The start of the truncation mutants of E6-AP and RSP5, which cannot
form thioester complexes with ubiquitin, are indicated by arrows. Amino acid residues conserved among most of the hect domain proteins are
indicated in bold. In B, the sequence of the approximately 80 C-terminal amino acids of hect domains is shown, for which only limited sequence
information is available. The sequences shown were derived by analyses of clones entered in EST data bases, and therefore sequence errors cannot
be excluded. However, it should be noted that only sequences were considered, for which several EST clones are available. Accession numbers for
hectH2-hectH2O (with hectH1 defined as E6-AP) are as follows. hectH2, D13635; hectH3, D25215; hectH4, D28476; hectH5, D42055; hectH6,
U50078; hectH7, U96113 in combination with H19362 and T93069; hectH8, U96114; hectH9, AB002310; hectH10, AB002315; hectH11, AB002320;
hectH12, W95857; hectH13, R06429 and W60127; hectH14, AA443004; hectH15, AA140512; hectH16, R23558 and AA194036; hectH17, N32787
and T62800; hectH18, H23082; hectH19, N24244 and N31202; hectH2O, N57610 and R20250.
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The hect Domain of E6-AP Cannot Be Replaced by Other hect
Domains in the Ubiquitination of p53—The studies presented
above are in support of the hypothesis that hect domain pro-
teins have a modular structure consisting of a conserved cata-
lytic C-terminal domain (i.e. the hect domain) and different
N-terminal extensions that determine the substrate specificity
of the respective hect domain protein. If this is indeed the case,
it may be possible to generate fusion proteins consisting of the
hect domain fused to an unrelated protein or region of a protein
that is known to mediate interaction with a protein of choice.
Such fusion proteins could then be used to target proteins that
otherwise would not be recognized by hect domain proteins
selectively for ubiquitin-mediated degradation. In a first at-
tempt to test the feasibility of this approach, a cDNA encoding
a chimeric protein consisting of amino acid residues 200–491 of
E6-AP and the hect domain of hectH6 (amino acid residues
4495–4861) (Fig. 6A) was constructed, and the chimeric protein
was expressed as a GST fusion protein in E. coli for the follow-
ing reasons. (i) The 75-kDa form of E6-AP, which starts at
amino acid 200 of E6-AP isoform 1 (22), has been shown to
contain the regions that are necessary and sufficient to bind to
the HPV E6 oncoprotein and to p53 in the presence of the HPV
E6 oncoprotein (see Fig. 6A) (28), and (ii) the 75-kDa form of
E6-AP expressed as a GST fusion protein in E. coli has been
shown to facilitate ubiquitination of an artificial E6-E7 fusion
protein as well as of p53 in the presence of the HPV E6 onco-
protein (16). The resulting E6-AP/hectH6 chimeric protein was
purified by glutathione affinity chromatography and tested for
ubiquitin thioester complex formation, binding to the E6-E7
fusion protein as well as to p53, and ubiquitination of the
E6-E7 fusion protein and p53 (Fig. 6, B–D). As controls, the
75-kDa form of E6-AP and the hect domain of E6-AP expressed
as GST fusion proteins were used.
As shown in Fig. 6B, the 75-kDa form of E6-AP, as well as the
E6-AP/hectH6 chimeric protein, were able to form thioester
complexes with ubiquitin in the presence of UbcH5. In addi-
tion, both proteins bound with a similar efficiency to the E6-E7
fusion protein, and both bound to p53 in the presence of the
HPV E6 oncoprotein, although the E6-AP/hectH6 chimeric pro-
tein was reproducibly less efficient in binding p53 than the
75-kDa form of E6-AP (Fig. 6C). In contrast to the 75-kDa form
of E6-AP, however, ubiquitination of neither the E6-E7 fusion
protein nor p53 was observed in the presence of the chimeric
protein (Fig. 6D). Taken together, these results suggest that
binding of a hect domain protein to a potential substrate pro-
tein is not sufficient to induce ubiquitination of the substrate
protein.
FIG. 4. Preferential interaction of human hect domain pro-
teins with UbcH5 or UbcH7. The hect domain of the respective
human hect domain proteins (hectH2-hectH7, hectH9) was generated
in rabbit reticulocyte lysate in the presence of L-[35S]methionine. Unlike
the experiments performed with E6-AP and RSP5 (see Fig. 1 and Fig.
2), the respective radiolabeled proteins were not partially purified by
anion exchange chromatography but were directly tested for ubiquitin
(Ub) thioester complex formation in the absence (input) or presence of
GST-ubiquitin and recombinant UbcH1 (1), UbcH5 (5), UbcH6 (6), and
UbcH7 (7) under standard conditions (see “Experimental Procedures”).
After 5 min at 25 °C, reactions were stopped in the absence (2DTT) or
in the presence (1DTT) of a reducing agent and subjected to SDS-
polyacrylamide gel electrophoresis followed by fluorography. Repre-
sentative examples of such assays are shown for hectH6 (represents a
recently identified protein termed p532 (23, 24)) (A) and hectH7 (B).
The results obtained for all the hect domains tested are summarized in
C. 1, indicates that ubiquitin thioester formation was most efficient in
the presence of the respective E2 (UbcH5 or UbcH7); 1/2, ubiquitin
thioester formation was observed in the presence of the respective E2
but with a significantly reduced efficiency compared with the other E2.
Running positions of unmodified hect domains as well as of the respec-
tive thioester adducts with GST-ubiquitin are indicated. It should be
noted that since the translates used were not partially purified, thio-
ester formation was observed even in the absence of recombinant E2s,
at least for some hect domains. This is explained by the fact that rabbit
reticulocyte lysate contains E2 activities that can substitute for UbcH5
and UbcH7 in E6-AP-dependent ubiquitination assays (16, 26, 27, 29,
30) and thus can be considered functionally equivalent to UbcH5 or
UbcH7.
FIG. 5. Expression of human hect domain genes. A commercially
available blot (CLONTECH) containing poly(A)1 RNA derived from
different human tissues was probed with cDNAs encoding the respec-
tive hect domain as indicated. Northern blot analyses using in vitro
transcribed RNAs encoding the different hect domains, and these cDNA
probes revealed that there is no cross-hybridization among the hect
sequences used.2 However, cross-hybridization with mRNAs encoding
hect domain proteins not used in this study cannot be excluded. kb,
kilobases.
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DISCUSSION
A likely possibility to account for the observed specificity and
selectivity of ubiquitin-dependent degradation is the presence
of a number of different E2s and E3s, which have been pro-
posed to play a major role in substrate recognition. This hy-
pothesis is supported by the fact that S. cerevisiae, for instance,
encodes for 13 different E2s (4), and according to data base
searches, the human genome apparently encodes at least 20
different E2s.3 With the exception of S. cerevisiae UBR1 (5),
however, the molecular identity of E3s remained enigmatic
until recently. Similar to E2s, which are characterized by a
highly conserved catalytic region termed the ubiquitin-conju-
gating (UBC) domain (4), recent studies suggest that eukary-
otic cells encode at least two families of putative E3s. These are
the hect domain proteins (12, 13) and the so-called SCF com-
plexes (see Refs. 9 and 10 for further details). The family of hect
domain proteins was originally identified based on amino acid
sequence similarity of its members to the C-terminal region of
E6-AP. In support of the hypothesis that hect domain proteins
in general have E3 function, the present study revealed that
the hect domain of several different proteins is both necessary
and sufficient to form thioester complexes with ubiquitin in the
presence of distinct E2s. Thus, the hect domain can be considered
as being functionally equivalent to the UBC domain of E2s in
that it constitutes the catalytic domain of the hect family of E3s.
Data base searches indicate that the human genome encodes
at least 20 different human hect domain proteins. The ration-
ale for choosing the particular human hect domain proteins
used in this study was that when this study was initiated,
cDNAs encoding the full-length protein were available for five
of these (E6-AP, hectH2-hectH5). Subsequently, cDNAs encod-
ing the full-length protein for hectH6 (p532 (23, 24)), hectH7
(32), and hectH9 (see below) became available. For hectH7, a
cDNA was originally isolated encoding a C-terminal-truncated
protein (32), which is now complemented to a full-length pro-
tein by this study. hectH9 represents the human homolog to a
rat protein termed UREB1 (33). Initial interest in this protein
was raised, since it was described to consist of approximately
300 amino acids and, thus, to represent an N-terminal-trun-
cated hect domain. However, our own studies indicate that the
human homolog of UREB1 consists of at least 800 amino acids.2
Moreover, no evidence has been obtained to suggest that hu-
man cells contain an mRNA species encoding for a similar
truncated protein as has been described in rat cells.2 The
notion that the human homolog of UREB1 is a regular hect
domain protein insofar that it consists of a hect domain of
approximately 350 amino acids and an N-terminal extension is
further supported by a recent data base entry (accession num-
ber AB002310) indicating that human UREB1 consists of 1906
amino acids.
We previously suggested that hect domain proteins can be
classified into two groups based on their preferential interac-
tion with distinct E2s (27). This is supported by the finding that
some hect domains derived from different human proteins form
ubiquitin thioester complexes preferentially in the presence of
UbcH5, whereas others form thioester complexes preferentially
3 M. Scheffner, unpublished data.
FIG. 6. The hect domain of E6-AP cannot be replaced by other
hect domains in E6-AP-dependent ubiquitination of p53. A, a
schematic drawing of the 75-kDa form of E6-AP (16, 28) and of a
chimeric protein consisting of amino acid residues 200–491 of E6-AP
fused to amino acid residues 4495–4861 of hectH6 (p532 (23, 24)) is
shown. The regions of E6-AP involved in binding the HPV E6 oncopro-
tein and the tumor suppressor p53 in the presence of the HPV E6
oncoprotein (28) and the hect domain are indicated. The cysteine resi-
due of E6-AP (12) and p532 (S. E. Schwarz, J. L. Rosa, and M. Scheffner,
unpublished data) involved in ubiquitin thioester complex formation is
marked with an asterisk. The 75-kDa form of E6-AP, the chimeric
protein, and the hect domain of E6-AP were expressed in E. coli as GST
fusion proteins and tested for ubiquitin thioester complex formation
using 32P-labeled ubiquitin (B), binding to the E6-E7 fusion protein and
to p53 in the presence of the HPV E6 oncoprotein (C), and ubiquitina-
tion of the E6-E7 fusion protein and p53 (D) under conditions described
elsewhere (for details, see “Experimental Procedures”). The E6-E7 fu-
sion protein and p53 were generated in wheat germ extract in the
presence of L-[35S]methionine. The running positions of the respective
thioester adducts, free ubiquitin (Ub), the E6-E7 fusion protein, and
p53 are indicated in the respective autoradiographs. Highly ubiquiti-
nated forms of the E6-E7 fusion protein as well as of p53 are marked
with an asterisk. In B, thioester reactions stopped in the absence
(2DTT) or presence (1DTT) of a reducing agent are indicated.
The Human hect Domain Family 12153
in the presence of UbcH7. The only exception was hectH5, for
which complex formation with ubiquitin was not observed.
However, hectH5 represents the human homolog of murine
Nedd4, which was recently shown to have ubiquitin-protein
ligase activity in the presence of UbcH5 in vitro (34). This
indicates that hectH5 may have the ability to form ubiquitin
thioester complexes but that such complexes cannot be de-
tected in the system used in the present study. The hect do-
main of E6-AP as well as of RSP5 appears to be somewhat
different to the other hect domains in that the hect domain of
both appears to interact in vitro with UbcH5 as well as with
UbcH7. In contrast to these in vitro results, it was recently
reported that in the yeast two-hybrid system, interaction of
E6-AP can only be detected with UbcH7 and not with UbcH5,
whereas interaction of RSP5 was observed with UbcH5 but not
with UbcH7 (35). Therefore, further studies will be required to
determine which if any of the interactions observed in vitro and
in the two-hybrid system are of functional significance in vivo.
The finding that the hect domain is necessary and sufficient
to form thioester complexes with ubiquitin indicates that hect
domain proteins have a modular structure consisting of a cat-
alytic domain (i.e. the hect domain) and different N-terminal
extensions that determine the substrate specificity of the re-
spective hect domain protein. This suggests the attractive pos-
sibility that, by fusion to suitable protein binding domains, a
given hect domain could bind and ubiquitinate proteins that
normally would not be recognized. It should be noted that a
similar approach to target proteins for selective ubiquitination
and degradation was suggested in previous studies using the
HPV E6 oncoprotein (36) or certain E2s (37). In an attempt to
test the feasibility of this approach, the N-terminal region of
E6-AP was fused to the hect domain of hectH6 (p532). Although
the resulting E6-AP/hectH6 fusion protein could bind to an
artificial substrate protein of E6-AP with an efficiency similar
to E6-AP, ubiquitination of this protein was not observed.
Thus, binding of a hect domain protein to a potential target
protein may not be sufficient to induce ubiquitination, suggest-
ing that a substrate protein and a given hect domain protein
have to interact in a structurally well defined manner to allow
ubiquitination of the substrate protein. Furthermore, the fu-
sion protein was able to bind to p53 in the presence of the HPV
E6 oncoprotein but less efficiently than E6-AP. This suggests
that, at least in some cases, the hect domain contributes toward
defining the substrate specificity or, at least, in modulating the
binding efficiency of the respective hect domain protein.
The fact that the similarity among human hect domain pro-
teins is mostly limited to the hect domain indicates that differ-
ent hect domain proteins are involved in the recognition and
ubiquitination of different proteins. Mutations in the E6-AP
gene have been reported to be the cause of a familial neurolog-
ical disorder termed Angelman syndrome (38–40). However,
with the exception of a recent report suggesting that the hu-
man homolog of S. cerevisiae RAD23 constitutes a substrate of
E6-AP (35), substrate proteins of E6-AP in the absence of the
HPV E6 oncoprotein have not yet been identified. p532
(hectH6) was shown to interact with the small GTP-binding
protein ARF1 and, possibly, with certain Rab proteins (23, 24).
However, whether ARF1 and Rab proteins are targets of p532
or regulators of p532 activity or if the observed interaction is
unrelated to the proposed E3 activity of p532 is unknown at
present. Nedd4, the proposed murine homolog of hectH5, was
reported to bind to the epithelial Na1 channel (41). Further-
more, it was recently shown that the stability and function of
the epithelial Na1 channel is regulated by ubiquitination and
subsequent degradation (8). However, whether Nedd4 is indeed
involved in this process or not remains to be determined. Sim-
ilar to Nedd4, the N-terminal extension of at least two addi-
tional human hect domain proteins contains WW domains
(hectH7 and hectH8) (32), and both p532 (hectH6) and hectH3
contain RCC1-like motifs (23).2 WW domains have been impli-
cated in the binding of peptides containing PY and PY-like
domains (Ref. 32, and references therein), and it is suggested
that RCC1-like domains bind small GTP-binding proteins (23).
Again, however, substrates of these particular hect domain
proteins have not yet been identified. In conclusion, to further
understand the role of human hect domain proteins in ubiquitin-
dependent degradation, it will be necessary to define both their
respective cellular function and their target proteins.
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36. Scheffner, M. Münger, K., Huibregtse, J. M., and Howley, P. M. (1992) EMBO
J. 11, 2425–2431
37. Gosink, M. M., and Vierstra, R. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92,
9117–9121
38. Kishino, T., Lalande, M., and Wagstaff, J. (1997) Nat. Genet. 15, 70–73
39. Matsuura, T., Sutcliffe, J. S., Fang, P., Galjaard, R. J., Jiang, Y. H., Benton,
C. S., Rommens, J. M., and Beaudet, A. L. (1997) Nat. Genet. 15, 74–77
40. Albrecht, U., Sutcliffe, J. S., Cattanach, B. M., Beechey, C. V., Armstrong, D.,
Eichele, G., and Beaudet, A. L. (1997) Nat. Genet. 17, 75–78
41. Staub, O., Dho, S., Henry, P. C., Correa, J., Ishikawa, T., McGlade, J., and
Rotin, D. (1996) EMBO J. 15, 2371–2380
The Human hect Domain Family12154
